Lipids & metabolic liver disease
Implications of Expanded Advanced Fibrosis Screening Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease in Primary Care
Authors' conclusion
Expanded screening for advanced liver fibrosis would substantially increase the number of patients who need confirmatory testing for liver fibrosis, increasing cost and straining access.
Study context
- Population
- Primary care patients with T2DM or prediabetes and a FIB-4 score, 2022–2024
- Participants
- 8,366 patients
- Exposure
- T2DM vs prediabetes
- Outcome
- FIB-4 score in need of confirmatory fibrosis risk assessment
Main finding
As reported in the abstract
FIB-4 in need of confirmatory risk assessment
Patients with FIB-4 in need of confirmatory risk assessment
2064
25%
Increase in patients needing confirmatory assessment with expanded screening vs those with MASLD diagnoses (n = 228)
9.1 times
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | |
|---|---|---|
| FIB-4 at indeterminate risk or greaterFully adjusted model | 0.86 (0.77–0.96) | |
| 0.512Odds ratio (log scale) |
Original publication
Implications of Expanded Advanced Fibrosis Screening Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease in Primary Care. Endocr Pract. Published 29 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →